Shanghai Medicilon Inc. (SHA:688202)

Market Cap	7.21B
Revenue (ttm)	1.04B
Net Income (ttm)	-330.85M
Shares Out	133.67M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,477,135
Average Volume	6,355,844
Open	50.83
Previous Close	50.30
Day's Range	50.40 - 55.99
52-Week Range	23.30 - 55.99
Beta	0.75
RSI	83.17
Earnings Date	Aug 29, 2025

About Shanghai Medicilon

Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2,349
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688202

Financial Performance

In 2024, Shanghai Medicilon's revenue was 1.04 billion, a decrease of -24.01% compared to the previous year's 1.37 billion. Losses were -330.85 million, 896.2% more than in 2023.